ArticleCurrent oncology (Toronto, Ont.)2010
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.
Article in Current oncology (Toronto, Ont.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.Clinical colorectal cancer · 2018Pooled it
- Trial
- Trial
- Beyond Acute EGFR Blockade: Biological Basis and Clinical Evidence for Long-Term Nimotuzumab Therapy.Biomedicines · 2026Review
- Comparable survival outcome with anti-EGFR therapy in any treatment line in left-sided metastatic colorectal cancer.Journal of gastrointestinal oncology · 2026Article
- Cetuximab-induced Facial Hypertrichosis in a Woman Treated for Metastatic Colon Adenocarcinoma.Oman medical journal · 2026Article
- Cutaneous and systemic manifestations of EGFR inhibitor therapy: A case of PRIDE syndrome.Journal of family medicine and primary care · 2025Article
- Marine-Derived Yaequinolone Derivative CHNQD-02792 Suppresses Colorectal Cancer Cell Proliferation and Induces Apoptosis via MAPK Pathway Modulation.Marine drugs · 2025Article
- Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.Nanomaterials (Basel, Switzerland) · 2025Review
- Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia.Journal of health economics and outcomes research · 2025Article
- A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy.International journal of molecular sciences · 2024Review
- Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC.Frontiers in surgery · 2024Review
- Sotorasib with panitumumab in chemotherapy-refractory KRASNature medicine · 2024Article
- Article
- Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives.Cancers · 2023Review
- Article
- Current Targeted Therapy for Metastatic Colorectal Cancer.International journal of molecular sciences · 2023Review
- Gastrointestinal injury induced by immunomodulators: A review article.Therapeutic advances in gastroenterology · 2023Review
- Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges.International journal of molecular sciences · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis.EGFR is overexpressed in a variety of solid tumors, including colorectal cancer (CRC), and its overexpression is associated with poorer prognosis. One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies. While the monoclonal antibody EGFR inhibitors lack many of the severe side effects commonly observed with cytotoxic chemotherapy, they are associated with a set of unique dermatological toxicities. This paper reviews the safety profile of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.